1
|
Jin LJ, Lamster IB, Greenspan JS, Pitts
NB, Scully C and Warnakulasuriya S: Global burden of oral diseases:
Emerging concepts, management and interplay with systemic health.
Oral Dis. 22:609–619. 2016.PubMed/NCBI View Article : Google Scholar
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
3
|
Montero PH and Patel SG: Cancer of the
oral cavity. Surg Oncol Clin N Am. 24:491–508. 2015.PubMed/NCBI View Article : Google Scholar
|
4
|
Troiano G, Mastrangelo F, Caponio VCA,
Laino L, Cirillo N and Lo Muzio L: Predictive prognostic value of
tissue-based MicroRNA expression in oral squamous cell carcinoma: A
systematic review and meta-analysis. J Dent Res. 97:759–766.
2018.PubMed/NCBI View Article : Google Scholar
|
5
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320.
2005.PubMed/NCBI View
Article : Google Scholar
|
6
|
Ma L, Bajic VB and Zhang Z: On the
classification of long non-coding RNAs. RNA Biol. 10:925–933.
2013.PubMed/NCBI View Article : Google Scholar
|
7
|
Wang Y, Zhang X, Wang Z, Hu Q, Wu J, Li Y,
Ren X, Wu T, Tao X, Chen X, et al: LncRNA-p23154 promotes the
invasion-metastasis potential of oral squamous cell carcinoma by
regulating Glut1-mediated glycolysis. Cancer Lett. 434:172–183.
2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Zhang C, Bao C, Zhang X, Lin X, Pan D and
Chen Y: Knockdown of lncRNA LEF1-AS1 inhibited the progression of
oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.
Cancer Biol Ther. 20:1213–1222. 2019.PubMed/NCBI View Article : Google Scholar
|
9
|
Li M, Ning J, Li Z, Fei Q, Zhao C, Ge Y
and Wang L: Long noncoding RNA OIP5-AS1 promotes the progression of
oral squamous cell carcinoma via regulating miR-338-3p/NRP1 axis.
Biomed Pharmacother. 118(109259)2019.PubMed/NCBI View Article : Google Scholar
|
10
|
Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang
Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1
causes cisplatin resistance in osteosarcoma through inducing the
LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the
miR-340-5p. J Cell Biochem. 120:9656–9666. 2019.PubMed/NCBI View Article : Google Scholar
|
11
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015.PubMed/NCBI View Article : Google Scholar
|
12
|
Nagai H, Hasegawa S, Uchida F, Terabe T,
Ishibashi Kanno N, Kato K, Yamagata K, Sakai S, Kawashiri S, Sato
H, et al: MicroRNA-205-5p suppresses the invasiveness of oral
squamous cell carcinoma by inhibiting TIMP2 expression. Int J
Oncol. 52:841–850. 2018.PubMed/NCBI View Article : Google Scholar
|
13
|
Feng X, Luo Q, Wang H, Zhang H and Chen F:
MicroRNA-22 suppresses cell proliferation, migration and invasion
in oral squamous cell carcinoma by targeting NLRP3. J Cell Physiol.
233:6705–6713. 2018.PubMed/NCBI View Article : Google Scholar
|
14
|
Peng M and Pang C: MicroRNA-140-5p
inhibits the tumorigenesis of oral squamous cell carcinoma by
targeting p21-activated kinase 4. Cell Biol Int: Aug 8, 2019 (Epub
ahead of print). doi: 10.1002/cbin.11213.2019.
|
15
|
Fukumoto I, Koshizuka K, Hanazawa T,
Kikkawa N, Matsushita R, Kurozumi A, Kato M, Okato A, Okamoto Y and
Seki N: The tumor-suppressive microRNA-23b/27b cluster regulates
the MET oncogene in oral squamous cell carcinoma. Int J Oncol.
49:1119–1129. 2016.PubMed/NCBI View Article : Google Scholar
|
16
|
Liu B, Chen W, Cao G, Dong Z, Xu J, Luo T
and Zhang S: MicroRNA-27b inhibits cell proliferation in oral
squamous cell carcinoma by targeting FZD7 and Wnt signaling
pathway. Arch Oral Biol. 83:92–96. 2017.PubMed/NCBI View Article : Google Scholar
|
17
|
Zhu J, Zou Z, Nie P, Kou X, Wu B, Wang S,
Song Z and He J: Downregulation of microRNA-27b-3p enhances
tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1
expression. Cell Death Dis. 7(e2454)2016.PubMed/NCBI View Article : Google Scholar
|
18
|
Zhang G, Tian X, Li Y, Wang Z, Li X and
Zhu C: miR-27b and miR-34a enhance docetaxel sensitivity of
prostate cancer cells through inhibiting epithelial-to-mesenchymal
transition by targeting ZEB1. Biomed Pharmacother. 97:736–744.
2018.PubMed/NCBI View Article : Google Scholar
|
19
|
Liu B, Cao G, Dong Z and Guo T: Effect of
microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous
cell carcinoma via FZD7 signaling pathway. Oncol Lett. 18:667–673.
2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Nenasheva VV, Nikolaev AI, Martynenko AV,
Kaplanskaya IB, Bodemer W, Hunsmann G and Tarantul VZ: Differential
gene expression in HIV/SIV-associated and spontaneous lymphomas.
Int J Med Sci. 2:122–128. 2005.PubMed/NCBI View Article : Google Scholar
|
21
|
Wang T, Ren Y, Liu R, Ma J, Shi Y, Zhang L
and Bu R: miR-195-5p suppresses the proliferation, migration, and
invasion of oral squamous cell carcinoma by targeting TRIM14.
Biomed Res Int. 2017(7378148)2017.PubMed/NCBI View Article : Google Scholar
|
22
|
Wang X, Guo H, Yao B and Helms J: miR-15b
inhibits cancer-initiating cell phenotypes and chemoresistance of
cisplatin by targeting TRIM14 in oral tongue squamous cell cancer.
Oncol Rep. 37:2720–2726. 2017.PubMed/NCBI View Article : Google Scholar
|
23
|
Tan Z, Song L, Wu W, Zhou Y, Zhu J, Wu G,
Cao L, Song J, Li J and Zhang W: TRIM14 promotes chemoresistance in
gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.
Oncogene. 37:5403–5415. 2018.PubMed/NCBI View Article : Google Scholar
|
24
|
Song L, Duan P, Gan Y, Li P, Zhao C, Xu J,
Zhang Z and Zhou Q: Silencing LPAATβ inhibits tumor growth of
cisplatin-resistant human osteosarcoma in vivo and in
vitro. Int J Oncol. 50:535–544. 2017.PubMed/NCBI View Article : Google Scholar
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
26
|
Xu W, Chang J, Du X and Hou J: Long
non-coding RNA PCAT-1 contributes to tumorigenesis by regulating
FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother.
95:1112–1118. 2017.PubMed/NCBI View Article : Google Scholar
|
27
|
Li S, Chen X, Liu X, Yu Y, Pan H, Haak R,
Schmidt J, Ziebolz D and Schmalz G: Complex integrated analysis of
lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. Oral Oncol.
73:1–9. 2017.PubMed/NCBI View Article : Google Scholar
|
28
|
Schober P, Boer C and Schwarte LA:
Correlation coefficients: Appropriate use and interpretation.
Anesth Analg. 126:1763–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
29
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009.PubMed/NCBI View Article : Google Scholar
|
30
|
Stordal B, Pavlakis N and Davey R: A
systematic review of platinum and taxane resistance from bench to
clinic: An inverse relationship. Cancer Treat Rev. 33:688–703.
2007.PubMed/NCBI View Article : Google Scholar
|
31
|
Fang Z, Chen W, Yuan Z, Liu X and Jiang H:
LncRNA-MALAT1 contributes to the cisplatin-resistance of lung
cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed
Pharmacother. 101:536–542. 2018.PubMed/NCBI View Article : Google Scholar
|
32
|
Fang Z, Zhao J, Xie W, Sun Q, Wang H and
Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance
of oral squamous cell carcinoma by sunppressing miR-184 expression.
Cancer Med. 6:2897–2908. 2017.PubMed/NCBI View Article : Google Scholar
|
33
|
Arunkumar G, Anand S, Raksha P,
Dhamodharan S, Prasanna Srinivasa Rao H, Subbiah S, Murugan AK and
Munirajan AK: LncRNA OIP5-AS1 is overexpressed in undifferentiated
oral tumors and integrated analysis identifies as a downstream
effector of stemness-associated transcription factors. Sci Rep.
8(7018)2018.PubMed/NCBI View Article : Google Scholar
|
34
|
Sun CC, Zhang L, Li G, Li SJ, Chen ZL, Fu
YF, Gong FY, Bai T, Zhang DY, Wu QM and Li DJ: The lncRNA PDIA3P
interacts with miR-185-5p to modulate oral squamous cell carcinoma
progression by targeting cyclin D2. Mol Ther Nucleic Acids.
9:100–110. 2017.PubMed/NCBI View Article : Google Scholar
|
35
|
Chang SM and Hu WW: Long non-coding RNA
MALAT1 promotes oral squamous cell carcinoma development via
microRNA-125b/STAT3 axis. J Cell Physiol. 233:3384–3396.
2018.PubMed/NCBI View Article : Google Scholar
|
36
|
Zhou RS, Zhang EX, Sun QF, Ye ZJ, Liu JW,
Zhou DH and Tang Y: Integrated analysis of lncRNA-miRNA-mRNA ceRNA
network in squamous cell carcinoma of tongue. BMC Cancer.
19(779)2019.PubMed/NCBI View Article : Google Scholar
|
37
|
Cao F and Yin LX: miR-122 enhances
sensitivity of hepatocellular carcinoma to oxaliplatin via
inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol.
106:34–43. 2019.PubMed/NCBI View Article : Google Scholar
|
38
|
Wang Q, Geng F, Zhou H, Chen Y, Du J,
Zhang X, Song D and Zhao H: MDIG promotes cisplatin resistance of
lung adenocarcinoma by regulating ABC transporter expression via
activation of the WNT/β-catenin signaling pathway. Oncol Lett.
18:4294–4307. 2019.PubMed/NCBI View Article : Google Scholar
|
39
|
Qiao CY, Qiao TY, Jin H, Liu LL, Zheng MD
and Wang ZL: LncRNA KCNQ1OT1 contributes to the cisplatin
resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14
axis. Eur Rev Med Pharmacol Sci. 241:200–212. 2020.PubMed/NCBI View Article : Google Scholar
|